{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T16:19:12Z","timestamp":1782058752237,"version":"3.54.5"},"reference-count":28,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Clinical Toxicology"],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.1080\/15563650.2023.2283391","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:23:35Z","timestamp":1701447815000},"page":"952-955","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time"],"prefix":"10.1080","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-596X","authenticated-orcid":false,"given":"Andrew I.","family":"Stolbach","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8362-2013","authenticated-orcid":false,"given":"Maryann E.","family":"Mazer-Amirshahi","sequence":"additional","affiliation":[{"name":"MedStar Washington Hospital Center, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9551-3922","authenticated-orcid":false,"given":"Lewis S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Rutgers New Jersey Medical School, Newark, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7714-8826","authenticated-orcid":false,"given":"Jon B.","family":"Cole","sequence":"additional","affiliation":[{"name":"Minnesota Poison Control System, Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, MN, USA"},{"name":"Department of Emergency Medicine, University of Minnesota Medical School, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"Centers for Disease Control and Prevention. Drug overdose deaths remained high in 2021 [Internet]. 2023 [cited 2023 Sep 18]. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html."},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9608"},{"key":"e_1_3_3_4_1","unstructured":"U.S. Food and Drug Administration Ohmeda Pharmaceutical Products Division Inc. Investigational new drug approval letter for nalmefene hydrochloride injection (Revex\u00ae) [Internet]. 1995 [cited 2023 Sep 4]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/pre96\/020459Orig1s000rev.pdf."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108019"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06125-5"},{"key":"e_1_3_3_7_1","unstructured":"kaleo inc. Naloxone Package Insert [Internet]. 2022 [cited 2023 Aug 17]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215457s000lbl.pdf."},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.256115"},{"key":"e_1_3_3_9_1","unstructured":"Purdue Pharmaceuticals LP. Nalmefene hydrochloride injection package insert [Internet]. 2021 [cited 2023 Jul 18]. https:\/\/www.accessdata.fda.gov\/spl\/data\/d4bb0797-a4ed-4ed4-9904-604433eea4ff\/d4bb0797-a4ed-4ed4-9904-604433eea4ff.xml."},{"key":"e_1_3_3_10_1","unstructured":"OPVEE\u00ae (nalmefene) nasal spray package insert [Internet]. www.opvee.com. 2023 [cited 2023 Jul 18]. https:\/\/opvee.com\/wp-content\/uploads\/2023\/07\/Combined-USPI_Patient-Info_IFU_Clean_05July2023.pdf."},{"key":"e_1_3_3_11_1","first-page":"141","article-title":"Nalmefene returns for reversal of opioid overdose","volume":"64","year":"2022","unstructured":"Nalmefene returns for reversal of opioid overdose. Med Lett Drugs Ther. 2022;64:141\u2013142.","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_3_3_12_1","unstructured":"Brescia-Oddo TL Shibuya RB Roca RA. NDA 217470 medical officer cross-discipline team leader and division director summary review [Internet]. U.S. Food and Drug Administration. 2023 [cited 2023 Oct 26]. https:\/\/www.fda.gov\/media\/171603\/download."},{"key":"e_1_3_3_13_1","unstructured":"U.S. Food and Drug Administration. Nalmefene Hydrochloride Injection Abbreviated New Drug Application Approval [Internet]. 2022 [cited 2023 Jul 18]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/212955Orig1s000ltr.pdf."},{"key":"e_1_3_3_14_1","first-page":"51282","article-title":"Determination that REVEX (nalmefene hydrochloride injection), 0.1 milligram base\/milliliter and 1.0 milligram base\/milliliter, was not withdrawn from sale for reasons of safety or effectiveness","volume":"82","author":"Department of Health and Human Services","year":"2017","unstructured":"Department of Health and Human Services. Determination that REVEX (nalmefene hydrochloride injection), 0.1 milligram base\/milliliter and 1.0 milligram base\/milliliter, was not withdrawn from sale for reasons of safety or effectiveness. Fed Regist. 2017;82:51282\u201351283.","journal-title":"Fed Regist"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0196-0644(05)80200-8"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0196-0644(99)70270-2"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198602000-00008"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199403000-00021"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.08.008"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098617744161"},{"issue":"11","key":"e_1_3_3_21_1","first-page":"1726","article-title":"Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in\u00a0vivo by a dual-detector system","volume":"38","author":"Kim S","year":"1997","unstructured":"Kim S, Wagner HN, Villemagne VL, et\u00a0al. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in\u00a0vivo by a dual-detector system. J Nucl Med. 1997;38(11):1726\u20131731.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.13034"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6537a6"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650701877374"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-019-00735-w"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230310001613958"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12680"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595239700186271"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2019.12.015"}],"updated-by":[{"DOI":"10.1080\/15563650.2023.2293385","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000}}],"container-title":["Clinical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15563650.2023.2283391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T21:52:43Z","timestamp":1727214763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15563650.2023.2283391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"alternative-id":["10.1080\/15563650.2023.2283391"],"URL":"https:\/\/doi.org\/10.1080\/15563650.2023.2283391","relation":{"correction":[{"id-type":"doi","id":"10.1080\/15563650.2023.2293385","asserted-by":"object"}]},"ISSN":["1556-3650","1556-9519"],"issn-type":[{"value":"1556-3650","type":"print"},{"value":"1556-9519","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ictx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ictx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}